For Q1, EPS is expected at $0.27, below Visible Alpha's $0.28 consensus, the note said. Organic sales are projected to decline 1.6%, against estimates of a 1.4% fall.

Although the outlook has become more challenging, the firm is likely to reiterate its guidance due to the limited visibility this early in the year, the report said.

UBS analysts said they would remain on the sidelines until there is greater visibility into an improvement in operating conditions amid "attractive" valuation.

UBS maintained its neutral rating with a $14 price target.

Price: 14.81, Change: +0.03, Percent Change: +0.20

http://www.mtnewswires.com
Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.